Brain-derived neurotrophic factor as a state-marker of mood episodes in bipolar disorders: A systematic review and meta-regression analysis

Journal of Psychiatric Research

Volumn 45, Issue 8, 2011, Pages 995-1004

  Fernandes, Brisa Simões ^a,b,c   Gama, Clarissa Severino ^a,b,c   Maria Ceresér, Keila ^a,b,c   Yatham, Lakshmi N ^d   Fries, Gabriel Rodrigo ^a,b   Colpo, Gabriela ^a,b   de Lucena, David ^a,b,c   Kunz, Mauricio ^a,b,c   Gomes, Fabiano Alves ^a,b,c   Kapczinski, Flavio ^a,b,c  

^a HOSPITAL DE CLÍNICAS DE PORTO ALEGRE   (Brazil)

^b Universidade Federal do Rio Grande do Sul ^*  (Brazil)

^c FEDERAL UNIVERSITY OF RIO GRANDE DO SUL   (Brazil)

^d UNIVERSITY OF BRITISH COLUMBIA   (Canada)

Author keywords

BDNF; Biomarker; Bipolar disorder; Brain derived neurotrophic factor; Meta analysis; Mood state

Indexed keywords

ANTIDEPRESSANT AGENT; ATYPICAL ANTIPSYCHOTIC AGENT; BIOLOGICAL MARKER; BRAIN DERIVED NEUROTROPHIC FACTOR; CARBAMAZEPINE; LITHIUM; MOOD STABILIZER; NEUROLEPTIC AGENT; VALPROIC ACID;

ADULT; ARTICLE; BIPOLAR DISORDER; DEPRESSION; DISEASE DURATION; DISEASE SEVERITY; EFFECT SIZE; HUMAN; IN VIVO STUDY; MANIA; MOOD CHANGE; PRIORITY JOURNAL; PROTEIN BLOOD LEVEL; SYSTEMATIC REVIEW;

ANTIDEPRESSIVE AGENTS; BIPOLAR DISORDER; BRAIN-DERIVED NEUROTROPHIC FACTOR; DATABASES, FACTUAL; HUMANS; REGRESSION ANALYSIS;

EID: 79958747390     PISSN: 00223956     EISSN: 18791379     Source Type: Journal    
DOI: 10.1016/j.jpsychires.2011.03.002     Document Type: Article

References (49)

1. Angst F., Stassen H.H., Clayton P.J., Angst J. Mortality of patients with mood disorders: follow-up over 34-38 years. Journal of Affective Disorders 2002, 68(2-3):167-181.
2. APA Diagnostic and statistical manual of mental disorders 2000, Washington, D.C.
3. Belmaker R.H. Bipolar disorder. The New England Journal of Medicine 2004, 351(5):476-486.
4. Berk M., Conus P., Lucas N., Hallam K., Malhi G.S., Dodd S., et al. Setting the stage: from prodrome to treatment resistance in bipolar disorder. Bipolar Disorders 2007, 9(7):671-678.
5. Berk M., Hallam K.T., McGorry P.D. The potential utility of a staging model as a course specifier: a bipolar disorder perspective. Journal of Affective Disorders 2007, 100(1-3):279-281.
6. Cunha A.B., Frey B.N., Andreazza A.C., Goi J.D., Rosa A.R., Goncalves C.A., et al. Serum brain-derived neurotrophic factor is decreased in bipolar disorder during depressive and manic episodes. Neuroscience Letters 2006, 398(3):215-219.
7. de Lucena D., Fernandes B.S., Berk M., Dodd S., Medeiros D.W., Pedrini M., et al. Improvement of negative and positive symptoms in treatment-refractory schizophrenia: a double-blind, randomized, placebo-controlled trial with memantine as add-on therapy to clozapine. The Journal of Clinical Psychiatry 2009, 70(10):1416-1423.
8. de Lucena D., Fernandes B.S., Kunz M., Fries G.R., Stertz L., Aguiar B., et al. Lack of association between serum brain-derived neurotrophic factor levels and improvement of schizophrenia symptoms in a double-blind, randomized, placebo-controlled trial of memantine as adjunctive therapy to clozapine. The Journal of Clinical Psychiatry 2010, 71(1):91-92.
9. de Oliveira G.S., Cereser K.M., Fernandes B., Kauer-Sant'anna M., Fries G.R., Stertz L., et al. Decreased brain-derived neurotrophic factor in medicated and drug-free bipolar patients. Journal of Psychiatric Research 2009, 43(14):1171-1174.
10. DerSimonian R., Laird N. Meta-analysis in clinical trials. Controlled Clinical Trials 1986, 7(3):177-188.
11. Dias V.V., Brissos S., Frey B.N., Andreazza A.C., Cardoso C., Kapczinski F. Cognitive function and serum levels of brain-derived neurotrophic factor in patients with bipolar disorder. Bipolar Disorders 2009, 11(6):663-671.
12. Egger M., Schneider M. Davey Smith G. Spurious precision? Meta-analysis of observational studies. BMJ (Clinical Research Ed.) 1998, 316(7125):140-144.
13. Egger M., Davey Smith G., Schneider M., Minder C. Bias in meta-analysis detected by a simple, graphical test. BMJ (Clinical Research Ed.) 1997, 315(7109):629-634.
14. Egger M., Zellweger-Zahner T., Schneider M., Junker C., Lengeler C., Antes G. Language bias in randomised controlled trials published in English and German. Lancet 1997, 350(9074):326-329.
15. Ernfors P., Wetmore C., Olson L., Persson H. Identification of cells in rat brain and peripheral tissues expressing mRNA for members of the nerve growth factor family. Neuron 1990, 5(4):511-526.
16. Fernandes B.S., Gama C.S., Kauer-Sant'anna M., Lobato M.I., Belmonte-de-Abreu P., Kapczinski F. Serum brain-derived neurotrophic factor in bipolar and unipolar depression: a potential adjunctive tool for differential diagnosis. Journal of Psychiatric Research 2009, 43(15):1200-1204.
17. Fernandes B., Gama C.S., Massuda R., Torres M., Camargo D., Kunz M., et al. Serum brain-derived neurotrophic factor (BDNF) is not associated with response to electroconvulsive therapy (ECT): a pilot study in drug resistant depressed patients. Neuroscience Letters 2009, 453(3):195-198.
18. Fernandes B.S., Massuda R., Torres M., Camargo D., Fries G.R., Gama C.S., et al. Improvement of schizophrenia with electroconvulsive therapy and serum brain-derived neurotrophic factor levels: lack of association in a pilot study. Psychiatry and Clinical Neuroscience 2010, 64(6):663-665.
19. Fernandes B.S., Gama C.S., Walz J.C., Ceresér K.M., Fries G.R., Colpo G., et al. Increased neurotrophin-3 in drug-free subjects with bipolar disorder during manic and depressive episodes. Journal of Psychiatric Research 2010, 44(9):561-565.
20. Frey B.N., Andreazza A.C., Cereser K.M., Martins M.R., Valvassori S.S., Reus G.Z., et al. Effects of mood stabilizers on hippocampus BDNF levels in an animal model of mania. Life Sciences 2006, 79(3):281-286.
21. Gama C.S., Andreazza A.C., Kunz M., Berk M., Belmonte-de-Abreu P.S., Kapczinski F. Serum levels of brain-derived neurotrophic factor in patients with schizophrenia and bipolar disorder. Neuroscience Letters 2007, 420(1):45-48.
22. Goldstein T.R., Birmaher B., Axelson D., Goldstein B.I., Gill M.K., Esposito-Smythers C., et al. Psychosocial functioning among bipolar youth. Journal of Affective Disorders 2009, 114(1-3):174-183.
23. Higgins J.P., Thompson S.G. Quantifying heterogeneity in a meta-analysis. Statistics in Medicine 2002, 21(11):1539-1558.
24. Higgins J.P., Thompson S.G., Deeks J.J., Altman D.G. Measuring inconsistency in meta-analyses. BMJ (Clinical Research Ed.) 2003, 327(7414):557-560.
25. Huston P., Naylor C.D. Health services research: reporting on studies using secondary data sources. CMAJ: Canadian Medical Association Journal 1996, 155(12):1697-1709.
26. Kapczinski F., Frey B.N., Andreazza A.C., Kauer-Sant'Anna M., Cunha A.B., Post R.M. Increased oxidative stress as a mechanism for decreased BDNF levels in acute manic episodes. Revista brasileira de psiquiatria 2008, 30(3):243-245.
27. Kapczinski F., Fernandes B.S., Kauer-Sant'Anna M., Gama C.S., Yatham L., Berk M. The concept of staging in bipolar disorder: the role of BDNF and TNF-alpha as biomarkers. Acta Neuropsychiatrica 2009, 21:272-274.
28. Karege F., Bondolfi G., Gervasoni N., Schwald M., Aubry J.M., Bertschy G. Low brain-derived neurotrophic factor (BDNF) levels in serum of depressed patients probably results from lowered platelet BDNF release unrelated to platelet reactivity. Biological Psychiatry 2005, 57(9):1068-1072.
29. Kauer-Sant'anna M., Kapczinski F., Andreazza A.C., Bond D.J., Lam R.W., Trevor Young L., et al. Brain-derived neurotrophic factor and inflammatory markers in patients with early- vs. late-stage bipolar disorder. The International Journal of Neuropsychopharmacology 2008, 1-12.
30. Langan C., Doyle K., Kelly J., Emsell L., Skinner R., McDonald C. Serum BDNF levels in euthymic bipolar disorder: preliminary results from the Galwey bipolar study. Bipolar Disorders 2009, 11(Suppl. 1):56.
31. Lau J., Ioannidis J.P., Schmid C.H. Quantitative synthesis in systematic reviews. Annals of Internal Medicine 1997, 127(9):820-826.
32. Lee H.Y., Kim Y.K. Plasma brain-derived neurotrophic factor as a peripheral marker for the action mechanism of antidepressants. Neuropsychobiology 2008, 57(4):194-199.
33. Le-Niculescu H., Kurian S.M., Yehyawi N., Dike C., Patel S.D., Edenberg H.J., et al. Identifying blood biomarkers for mood disorders using convergent functional genomics. Molecular Psychiatry 2009, 14(2):156-174.
34. Liberati A., Altman D.G., Tetzlaff J., Mulrow C., Gotzsche P.C., Ioannidis J.P., et al. The PRISMA statement for reporting systematic reviews and meta-analyses of studies that evaluate health care interventions: explanation and elaboration. Annals of Internal Medicine 2009, 151(4):65-94.
35. Machado-Vieira R., Dietrich M.O., Leke R., Cereser V.H., Zanatto V., Kapczinski F., et al. Decreased plasma brain derived neurotrophic factor levels in unmedicated bipolar patients during manic episode. Biological Psychiatry 2007, 61(2):142-144.
36. Mackin P., Gallagher P., Watson S., Young A.H., Ferrier I.N. Changes in brain-derived neurotrophic factor following treatment with mifepristone in bipolar disorder and schizophrenia. The Australian and New Zealand Journal of Psychiatry 2007, 41(4):321-326.
37. Manji H.K., Drevets W.C., Charney D.S. The cellular neurobiology of depression. Nature Medicine 2001, 7(5):541-547.
38. Marano C.M., Phatak P., Vemulapalli U.R., Sasan A., Nalbandyan M.R., Ramanujam S., et al. Increased plasma concentration of brain-derived neurotrophic factor with electroconvulsive therapy: a pilot study in patients with major depression. The Journal of Clinical Psychiatry 2007, 68(4):512-517.
39. Moher D., Liberati A., Tetzlaff J., Altman D.G. Preferred reporting items for systematic reviews and meta-analyses: the PRISMA statement. Annals of Internal Medicine 2009, 151(4):264-269. PRISMA Group.
40. Monteleone P., Serritella C., Martiadis V., Maj M. Decreased levels of serum brain-derived neurotrophic factor in both depressed and euthymic patients with unipolar depression and in euthymic patients with bipolar I and II disorders. Bipolar Disorders 2008, 10(1):95-100.
41. Palomino A., Vallejo-Illarramendi A., Gonzalez-Pinto A., Aldama A., Gonzalez-Gomez C., Mosquera F., et al. Decreased levels of plasma BDNF in first-episode schizophrenia and bipolar disorder patients. Schizophrenia Research 2006, 86(1-3):321-322.
42. Pan W., Banks W.A., Fasold M.B., Bluth J., Kastin A.J. Transport of brain-derived neurotrophic factor across the blood-brain barrier. Neuropharmacology 1998, 37(12):1553-1561.
43. Pandey G.N., Ren X., Rizavi H.S., Conley R.R., Roberts R.C., Dwivedi Y. Brain-derived neurotrophic factor and tyrosine kinase B receptor signalling in post-mortem brain of teenage suicide victims. The International Journal of Neuropsychopharmacology 2008, 11(8):1047-1061.
44. Poo M.M. Neurotrophins as synaptic modulators. Nature Reviews Neuroscience 2001, 2(1):24-32.
45. Tramontina J., Frey B.N., Andreazza A.C., Zandona M., Santin A., Kapczinski F. Val66met polymorphism and serum brain-derived neurotrophic factor levels in bipolar disorder. Molecular Psychiatry 2007, 12(3):230-231.
46. Tramontina J.F., Andreazza A.C., Kauer-Sant'anna M., Stertz L., Goi J., Chiarani F., et al. Brain-derived neurotrophic factor serum levels before and after treatment for acute mania. Neuroscience Letters 2009, 452(2):111-113.
47. Yatham L.N., Kapczinski F., Andreazza A.C., Trevor Young L., Lam R.W., Kauer-Sant'anna M. Accelerated age-related decrease in brain-derived neurotrophic factor levels in bipolar disorder. The International Journal of Neuropsychopharmacology 2009, 12(1):137-139.
48. Yoshimura R., Nakano Y., Hori H., Ikenouchi A., Ueda N., Nakamura J. Effect of risperidone on plasma catecholamine metabolites and brain-derived neurotrophic factor in patients with bipolar disorders. Human Psychopharmacology 2006, 21(7):433-438.
49. Zintzaras E., Hadjigeorgiou G.M. Association of paraoxonase 1 gene polymorphisms with risk of Parkinson's disease: a meta-analysis. Journal of Human Genetics 2004, 49(9):474-481.